He Y, Zhang WY, Gong M, Huang JY, Tang N, Feng T, Wei GH, He TC, Bi Y: Low serum concentration facilitates the differentiation of hepatic progenitor cells. Saudi Med J 2011, 32:128–134.PubMed 30. Nabekura T, Yamaki T, Hiroi T, Ueno K, Kitagawa S: Inhibition of anticancer
drug efflux transporter P-glycoprotein by rosemary phytochemicals. Pharmacol Res 2010, 61:259–263.PubMedCrossRef 31. Nabekura T, Yamaki T, Kitagawa S: Effects of chemopreventive citrus phytochemicals on human P-glycoprotein and multidrug resistance protein 1. Eur J Pharmacol 2008, 600:45–49.PubMedCrossRef 32. Shah selleck JP, Kumar S, Bryant CS, Ali-Fehmi R, Malone JM Jr, Deppe G, Morris RT: A population-based analysis of 788 cases of yolk sac tumors: A comparison of males and females. Int J Cancer 2008, 123:2671–2675.PubMedCrossRef 33. de La Motte Rouge T, Pautier P, Duvillard P, Rey A, Morice P, Haie-Meder C, Kerbrat P, Culine S, Troalen F, Lhommé C: Survival and reproductive function of 52 women treated with surgery and bleomycin, etoposide, cisplatin (BEP) chemotherapy for ovarian yolk sac tumor. Ann Oncol 2008, 19:1435–1441.PubMedCrossRef 34. Mhaidat NM, Alshogran OY, Khabour OF, Alzoubi KH, Matalka II, Haddadin WJ, Mahasneh IO, Aldaher AN: Multi-drug resistance 1 genetic polymorphism and prediction of chemotherapy response in Hodgkin’s Lymphoma. J Exp Clin Cancer Res 2011, 30:68.PubMedCrossRef 35. Mizutani T, Masuda
M, Nakai E, Furumiya K, Togawa H, Nakamura Y, Kawai Y, Nakahira K, Shinkai S, Y-27632 ic50 TCL Takahashi K: Genuine functions of P-glycoprotein (ABCB1). Curr Drug Metab 2008, 9:167–174.PubMedCrossRef 36. Maier P, Fleckenstein K, Li L, Laufs S, Zeller WJ, Baum C, Fruehauf S, Herskind C, Wenz F: Overexpression of MDR1 using a retroviral vector differentially regulates genes involved in detoxification and apoptosis and confers radioprotection. Radiat Res 2006, 166:463–473.PubMedCrossRef 37. Achard-Joris
M, Bourdineaud JP: Heterologous expression of bacterial and human multidrug resistance proteins protect Escherichia coli against mercury and zinc contamination. Biometals 2006, 19:695–704.PubMedCrossRef 38. Jackson AL, Linsley PS: Recognizing and avoiding siRNA off-target effects for target identification and therapeutic application. Nat Rev Drug Discov 2010, 9:57–67.PubMedCrossRef 39. Caffrey DR, Zhao J, Song Z, Schaffer ME, Haney SA, Subramanian RR, Seymour AB, Hughes JD: siRNA Off-Target Effects Can Be Reduced at Concentrations That Match Their Individual Potency. PLoS One 2011, 6:e21503.PubMedCrossRef 40. Parsons BD, Schindler A, Evans DH, Foley E: A direct phenotypic comparison of siRNA pools and multiple individual duplexes in a functional assay. PLoS One 2009, 4:e8471.PubMedCrossRef 41. Hsieh AC, Bo R, Manola J, Vazquez F, Bare O, Khvorova A, Scaringe S, Sellers WR: A library of siRNA duplexes targeting the phosphoinositide 3-kinase pathway: determinants of gene silencing for use in cell-based screens. Nucleic Acids Res 2004, 32:893–901.PubMedCrossRef 42.